[11] Preclinical and biochemical studies describe receptor activity at GLP-1, GIP, and glucagon receptors
Multidisc J Womens Health.2015;4(1)
While the ADJUNCT TWO also reported an increased rate ratio of symptomatic hypoglycemia of 1.33 on 1.2 mg liraglutide, events were not significantly different with the 1.8 mg dose in that study
Implications for Treatment Persistence and Outcomes Taken together, discontinuations and interruptions in GLP-1RA use were common in this cohort, particularly during the first year of treatment
Other health conditions, such as obesity, smoking, diabetes, or heart disease, may have contributed
A typical weekly research dose of 6mg (2mg three times weekly) represents approximately 0.027% of the estimated toxic dose